Mr Brett Carter will succeed Dr Warwick Tong who has led CTx for the past 6 years and who will continue to provide services to the organisation in an advisory capacity. These changes reflect a transition plan agreed between Dr Tong and the CTx Board to evolve the organisation from a Federally supported Cooperative Research Centre (CRC) into an independent and self-sustainable organisation.

Commenting on the appointment, Dr Tony Evans Chair of CTx, said: “We are delighted to appoint Brett as Chief Executive Officer. Brett has excellent management skills, extensive industry experience and a track record of executing pharmaceutical deals, making him the ideal candidate to lead CTx moving forward. I would like to thank Warwick for his dedicated leadership of the organisation over the past 6 years. Warwick has made many contributions to CTx however I would like to specifically highlight his involvement in the PRMT5 licensing deal to Merck, which was one of Australia’s largest ever pre-clinical asset licensing deals.”

Commenting on the appointment, Mr Carter, said: “Cancer is Australia’s leading cause of pre-mature death and CTx’s unique and highly successful business model has resulted in the development of drug products that have the potential to provide cures for cancer patients. I am very excited to be taking over the leadership of an organisation with such a strong culture of innovation and delivery.

To move from a medical research hub to a global biotechnology leader, Australia needs organisations like CTx, that build the drug discovery and development capability necessary to translate the country’s world class medical research into clinical and commercial outcomes.

I want to thank Warwick for his mentorship over the past year and I look forward to working with the CTx team and stakeholders as we embark on the next stage of the organisation’s evolution.”